Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $40 to $50.
Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $40 to $50.